Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.

Xu B, Abourbih S, Sircar K, Kassouf W, Mansure JJ, Aprikian A, Tanguay S, Brimo F.

Arch Pathol Lab Med. 2013 Oct;137(10):1326-36. doi: 10.5858/arpa.2012-0525-OA. Review.

PMID:
24079759
2.

Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.

Wang Y, Chen Y, Geng H, Qi C, Liu Y, Yue D.

Tumour Biol. 2015 Sep;36(9):7159-66. doi: 10.1007/s13277-015-3417-z.

PMID:
25877750
3.

Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.

Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J.

BJU Int. 2016 Feb;117(2):351-62. doi: 10.1111/bju.12702.

PMID:
24612432
4.

Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.

Lee HW, Choe M.

Pathol Int. 2012 Nov;62(11):735-41. doi: 10.1111/pin.12001.

PMID:
23121604
5.
6.

[Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].

Wang G, Qin W, Zheng J, Wei M, Zhou X, Wang H, Wen W.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Jan;29(1):82-4, 88. Chinese.

PMID:
23294722
7.

Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases.

Xu B, Abourbih S, Sircar K, Kassouf W, Aprikian A, Tanguay S, Brimo F.

Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):206-12. doi: 10.1097/PAI.0b013e31828ef24e.

PMID:
23702650
8.

The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.

Sakurai T, Bilim VN, Ugolkov AV, Yuuki K, Tsukigi M, Motoyama T, Tomita Y.

Biochem Biophys Res Commun. 2012 Jun 15;422(4):607-14. doi: 10.1016/j.bbrc.2012.05.035.

9.

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M.

BMC Cancer. 2010 Oct 4;10:524. doi: 10.1186/1471-2407-10-524.

10.

Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study.

Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J.

PLoS One. 2013 Nov 27;8(11):e81484. doi: 10.1371/journal.pone.0081484.

11.

EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.

Xu ZQ, Zhang L, Gao BS, Wan YG, Zhang XH, Chen B, Wang YT, Sun N, Fu YW.

Clin Transl Oncol. 2015 Jan;17(1):41-9. doi: 10.1007/s12094-014-1195-5.

PMID:
24986100
12.

Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.

Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, Ishii N, Dahiya R.

Cancer Res. 2015 Apr 1;75(7):1322-31. doi: 10.1158/0008-5472.CAN-14-2931.

13.

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).

Changchien YC, Tátrai P, Papp G, Sápi J, Fónyad L, Szendrői M, Pápai Z, Sápi Z.

J Transl Med. 2012 Oct 30;10:216. doi: 10.1186/1479-5876-10-216.

14.

EZH2 expression in invasive lobular carcinoma of the breast.

Roh S, Park SY, Ko HS, Sohn JS, Cha EJ.

World J Surg Oncol. 2013 Nov 22;11:299. doi: 10.1186/1477-7819-11-299.

15.

Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.

Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Chikamoto A, Watanabe M, Beppu T, Baba H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S667-75. doi: 10.1245/s10434-013-3135-y.

PMID:
23887863
16.

EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.

Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, Yang JS, Xu TP, Liu YW, Zou YF, Lu BB, Yin R, Zhang EB, Xu L, De W, Wang ZX.

Cell Death Dis. 2014 Jun 26;5:e1298. doi: 10.1038/cddis.2014.256.

17.

Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.

Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B.

Int J Gynecol Cancer. 2013 Jul;23(6):997-1005. doi: 10.1097/IGC.0b013e318296a265.

18.

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.

Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H.

Cancer. 2010 Jun 15;116(12):3015-24. doi: 10.1002/cncr.25128.

19.

Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.

Hinz S, Weikert S, Magheli A, Hoffmann M, Engers R, Miller K, Kempkensteffen C.

J Urol. 2009 Dec;182(6):2920-5. doi: 10.1016/j.juro.2009.08.014.

PMID:
19846140
20.

PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.

Ozcan A, de la Roza G, Ro JY, Shen SS, Truong LD.

Arch Pathol Lab Med. 2012 Dec;136(12):1541-51. doi: 10.5858/arpa.2012-0072-OA.

PMID:
23194047
Items per page

Supplemental Content

Support Center